NCT05253833 - Phase 2 to Assess Efficacy and Safety in AR882 Alone or in Combination With Allopurinol in Patients With Tophaceous Gout | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 12, 2022

Primary Completion Date

August 13, 2024

Study Completion Date

October 28, 2024

Conditions

GoutArthritis, GoutyHyperuricemiaGout Chronic

Interventions

DRUG

AR882 Dose 1

Solid Oral Capsule

DRUG

AR882 Dose 2

Solid Oral Capsule

DRUG

Allopurinol Tablet

Solid tablet

Trial Locations (12)

Arthrosi Investigative Site (303), Taichung

Arthrosi Investigative Site (201), Auckland

Arthrosi Investigative Site (406), Greensboro

Arthrosi Investigative Site (408), Myrtle Beach

Arthrosi Investigative Site (402), Tampa

Arthrosi Investigative Site (410), Birmingham

Arthrosi Investigative Site (409), Ann Arbor

Arthrosi Investigative Site (401), Dallas

Arthrosi Investigative Site (404), Boise

Arthrosi Investigative Site (403), Phoenix

Arthrosi Investigative Site (416), Sun City

Arthrosi Investigative Site (417), Tucson